Who are Intrathecal injection of pemetrexed's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pemetrexed + oral folinic acid rescue, Pemetrexed plus Carboplatin or Cisplatin, Bevacizumab and Pemetrexed/platinum, Pemetrexed+carboplatin/Cisplatin, Pemetrexed+Cisplatin or Carboplatin, Pemetrexed plus Pembrolizumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intrathecal-injection-of-pemetrexed.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Intrathecal injection of pemetrexed — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intrathecal injection of pemetrexed (Intrathecal injection of pemetrexed) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifolate antimetabolite. Area: Oncology.

marketed Antifolate antimetabolite Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Intrathecal injection of pemetrexed (Intrathecal injection of pemetrexed) — Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Pemetrexed inhibits multiple folate-dependent enzymes involved in nucleotide synthesis, disrupting DNA and RNA production in cancer cells when delivered directly into the cerebrospinal fluid.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Intrathecal injection of pemetrexed TARGET	Intrathecal injection of pemetrexed	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	marketed	Antifolate antimetabolite	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase
Pemetrexed + oral folinic acid rescue	Pemetrexed + oral folinic acid rescue	Radboud University Medical Center	marketed	Antifolate antimetabolite	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase
Pemetrexed plus Carboplatin or Cisplatin	Pemetrexed plus Carboplatin or Cisplatin	Avistone Biotechnology Co., Ltd.	phase 3	Antifolate antimetabolite combined with platinum-based chemotherapy	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase; DNA (platinum agents)
Bevacizumab and Pemetrexed/platinum	Bevacizumab and Pemetrexed/platinum	Sun Yat-sen University	phase 3	Combination therapy: monoclonal antibody (anti-VEGF) + antifolate + platinum chemotherapy	VEGF (bevacizumab); thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase (pemetrexed); DNA (platinum)
Pemetrexed+carboplatin/Cisplatin	Pemetrexed+carboplatin/Cisplatin	Suzhou Puhe Pharmaceutical Technology Co., LTD	phase 3	Antifolate antimetabolite + platinum-based chemotherapy combination	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase; DNA (platinum agents)
Pemetrexed+Cisplatin or Carboplatin	Pemetrexed+Cisplatin or Carboplatin	Sichuan Baili Pharmaceutical Co., Ltd.	phase 3	Antifolate antimetabolite + platinum-based chemotherapy combination	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase; DNA (platinum agents)
Pemetrexed plus Pembrolizumab	Pemetrexed plus Pembrolizumab	Hunan Province Tumor Hospital	phase 3	Antifolate antimetabolite + PD-1 inhibitor combination	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase (pemetrexed); PD-1 (pembrolizumab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifolate antimetabolite class)

Allist Pharmaceuticals, Inc. · 1 drug in this class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
Mundipharma K.K. · 1 drug in this class
Radboud University Medical Center · 1 drug in this class
Shanghai Miracogen Inc. · 1 drug in this class
The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intrathecal injection of pemetrexed — Competitive Intelligence Brief. https://druglandscape.com/ci/intrathecal-injection-of-pemetrexed. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab